Bioresorbable scaffolds: History and current knowledge

In recent years, the treatment of coronary atherosclerotic heart disease has achieved rapid development. Percutaneous coronary intervention (PCI) has become the first choice of treatment for patients with acute coronary syndrome and stable coronary artery disease. Over the last decade, drug-eluting stents (DESs) have remarkably reduced restenosis and the need for iterance after implantation of metallic stents. However, the implanted permanent metallic endovascular devices in the coronary artery to reestablish the patency of a stenotic artery have inherited pitfalls, including vascular inflammation, restenosis, and stent thrombosis. Bioresorbable scaffolds (BRSs) exhibit a new approach in coronary stent technology. In contrast to DESs, they offer transient scaffolding, thereby safeguarding acute gain and early vessel patency. The aim of this review is to describe the history and provide an update on the status of BRS, present the evidence from the clinical evaluation of BRS, and discuss this innovative technology and prospects for improved interventional cardiology